NDAOPHTHALMIC, OTICOINTMENT
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
HYDELTRASOL (prednisolone sodium phosphate) by Merck & Co. is clinical pharmacology naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.
Drug data last refreshed 19h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDELTRASOL (Prednisolone Sodium Phosphate) is a synthetic glucocorticoid steroid available as an ophthalmic and otic ointment formulation. It works by suppressing inflammatory processes and immune responses through glucocorticoid receptor activation. The sodium phosphate salt form enables rapid absorption and faster peak plasma levels compared to tablet formulations.
Pre-Launch
Pre-launch stage indicates emerging commercial infrastructure build with opportunities in launch planning, market access, and early field preparation roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many…
Worked on HYDELTRASOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.